NAMENDA Drug Patent Profile

When do Namenda patents expire, and what generic alternatives are available?

Namenda is a drug marketed by Allergan and Abbvie and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in NAMENDA is memantine hydrochloride. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the memantine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Namenda

A generic version of NAMENDA was approved as memantine hydrochloride by DR REDDYS LABS LTD on April 14^th, 2010.

Summary for NAMENDA

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	77
Patent Applications:	4,062
Drug Prices:	Drug price information for NAMENDA
What excipients (inactive ingredients) are in NAMENDA?	NAMENDA excipients list
DailyMed Link:	NAMENDA at DailyMed

See drug prices for NAMENDA

See drug sales revenues for NAMENDA

Recent Clinical Trials for NAMENDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Inova Health Care Services	PHASE2
University of Chicago	Phase 2/Phase 3
Children's Hospital Medical Center, Cincinnati	Early Phase 1

See all NAMENDA clinical trials

Pharmacology for NAMENDA

Drug Class	N-methyl-D-aspartate Receptor Antagonist
Mechanism of Action	NMDA Receptor Antagonists

Paragraph IV (Patent) Challenges for NAMENDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAMENDA	Tablets	memantine hydrochloride	5 mg and 10 mg	021487	14	2007-10-16

US Patents and Regulatory Information for NAMENDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	NAMENDA	memantine hydrochloride	SOLUTION;ORAL	021627-001	Apr 18, 2005		DISCN	Yes	No
Abbvie	NAMENDA XR	memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022525-004	Jun 21, 2010		DISCN	Yes	No	8,039,009*PED				Y
Abbvie	NAMENDA XR	memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022525-001	Jun 21, 2010		DISCN	Yes	No	8,039,009*PED				Y
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487-001	Oct 16, 2003		DISCN	Yes	No
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487-002	Oct 16, 2003		DISCN	Yes	No
Abbvie	NAMENDA XR	memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022525-003	Jun 21, 2010		DISCN	Yes	No	8,039,009*PED				Y

Expired US Patents for NAMENDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	NAMENDA	memantine hydrochloride	SOLUTION;ORAL	021627-001	Apr 18, 2005	5,614,560
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487-002	Oct 16, 2003	5,614,560
Abbvie	NAMENDA	memantine hydrochloride	TABLET;ORAL	021487-001	Oct 16, 2003	5,614,560

EU/EMA Drug Approvals for NAMENDA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merz Pharmaceuticals GmbH	Memantine Merz	memantine hydrochloride	EMEA/H/C/002711Treatment of patients with moderate to severe Alzheimer’s disease.	Authorised	no	no	no	2012-11-22

International Patents for NAMENDA

See the table below for patents covering NAMENDA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	94384
Canada	2014453	DERIVES D'ADAMANTANE UTILES DANS LA PREVENTION ET LE TRAITEMENT DE L'ISCHEMIE CEREBRALE (ADAMANTANE-DERIVATIVES IN THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA)
Switzerland	679208
German Democratic Republic	293493	VERWENDUNG VON ADAMANTAN-DERIVATEN ZUR PRAEVENTION UND BEHANDLUNG DER CEREBRALEN ISCHAEMIE
Germany	10299048
Germany	58905637

Supplementary Protection Certificates for NAMENDA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0392059	90988	Luxembourg
0392059	SPC/GB02/046	United Kingdom		PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
0392059	2002C/035	Belgium		PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
0392059	0290025-6	Sweden		PRODUCT NAME: MEMANTIN, 1-AMINO-3,5-DIMETYLADAMANTAN; REGISTRATION NO/DATE: EU/1/02/219/001 20020515

Last updated: July 21, 2026

Namenda (memantine) market dynamics and financial trajectory: pricing, share, exclusivity, and competitive pressure

Executive summary: Namenda (memantine) is a long-cycle central nervous system (CNS) therapy with limited near-term “IP-driven” entry risk because the core active ingredient is long off patent. Financial trajectory is driven less by patent exclusivity and more by: (1) payer-driven pricing and utilization management, (2) channel mix (brand vs generics), (3) pull-through from combination products and guideline positioning in Alzheimer’s disease, and (4) competitive intensity from multi-source generics and branded generics. The practical market dynamic is that Namenda has largely transitioned into a low-growth, share-scrapping environment where generics control volume while brands focus on contracting and pharmacy benefit leverage.

---

What is Namenda (memantine) and which indications drive revenue?

Short answer: Namenda is memantine, an NMDA receptor antagonist used in Alzheimer’s disease. Revenue is tied to Alzheimer’s-related treatment patterns across neurology and geriatrics.

Indication scope that supports demand

Namenda is marketed for:

• Moderate to severe Alzheimer’s disease (primary on-label framing in the US market).
• Combination use with donepezil is common in clinical practice and shapes formulary access.

Where sales usually come from (market structure)

• Chronic use with maintenance refills: demand is recurring, but volume growth is capped by prevalence maturity and mortality/attrition.
• Dose and titration patterns: create predictable cadence of prescriptions rather than episodic spikes.
• Formulary access: payer placement (preferred vs non-preferred) is the main swing factor once generics dominate.

---

How do generics and biosimilar-free dynamics affect Namenda pricing power?

Short answer: Namenda is not exposed to biologic-style biosimilar dynamics. It faces generic erosion and ongoing price competition across dosage forms.

Generic competition mechanics

• Multi-source generics typically compress net price over time through reimbursement benchmarks and PBM negotiations.
• Brand equity, when it persists, mainly supports switch resistance among certain prescribers, but payer policies usually drive volume transfer to lower-cost options.

Practical pricing and contracting outcomes

For long-held small molecules like memantine:

• Net price is usually dominated by AWP-to-NADAC rebates/discounts and PBM fee structures, not patent leverage.
• Brand survival depends on sustaining preferred positioning or limiting formulary switches via contract terms.

---

When does Namenda lose exclusivity and what does that mean for market share?

Short answer: The active ingredient memantine is long past active substance exclusivity. Market share shifts have already occurred in most geographies, so the current “exclusivity question” is less about brand protection and more about whether branded products still retain formulary access versus generics.

Exclusivity reality check (business impact)

Once active-ingredient protection expires:

• Volume typically transitions quickly to generics.
• Remaining brand revenue depends on contracting and pharmacy channel dynamics, not legal exclusivity.

What still can matter after ingredient expiry

• Line extensions (different salts, strengths, dosing regimens, extended-release vs immediate-release) can create incremental IP islands.
• Method-of-use and formulation patents can delay certain generic versions, but their financial impact is usually smaller than ingredient exclusivity for widely used CNS generics unless they block the most prescribed presentation.

---

What formulations are sold as Namenda and how do dosing forms influence competition?

Short answer: Namenda’s market impact hinges on whether payers prefer immediate-release vs extended-release presentations and how switching affects adherence and dosing convenience.

Common dosing/formulation patterns shaping procurement

• Immediate-release vs extended-release offerings affect:
  • day-to-day adherence
  • dosing frequency complexity
  • pharmacy stocking and substitution behavior
• If a specific presentation remains under stronger patent coverage longer than others, it can transiently reduce substitution risk.

Combination therapy as a demand stabilizer

• Combination regimens (memantine plus cholinesterase inhibitor) can improve persistence.
• That can translate into steadier demand even as monotherapy shifts to generics.

---

What Orange Book status applies to Namenda, and how does it affect Paragraph IV risk?

Short answer: Namenda’s major legal risk profile in the US is largely about whether any remaining listed patents cover specific marketed strengths or dosing forms. Paragraph IV risk is normally low for a product where the core active ingredient and key formulation patents are no longer relevant.

Paragraph IV landscape implications

• If the Orange Book listings for Namenda have already expired across key patents, new ANDA incentives fade.
• If any residual patents remain, generic challengers target those entries, potentially producing short-lived settlements or “design-around” launches.

Financial translation of Orange Book changes

When an Orange Book patent stack clears:

• generics increase share by enabling broader coverage at lower net cost
• PBMs push higher substitution
• brand volumes decline unless brand negotiates continued carve-outs

---

Which companies dominate Namenda competition and how does that reshape net revenue?

Short answer: Namenda’s competitive set is primarily generic manufacturers competing via ANDAs and branded generics. The brand’s net revenue typically declines as multi-source supply expands and payers standardize on lowest-cost options.

Typical competitor behaviors (what matters commercially)

• Price anchoring: generics use benchmark pricing and competitive contract bids.
• Formulary alignment: manufacturers support PBM placements and may fund adherence initiatives.
• Supply reliability: CNS chronic meds face fewer “supply substitution” tactics than injectables, but supply continuity still affects preferred status.

---

How strong is the patent estate for Namenda and what does it protect today?

Short answer: For memantine, the current practical patent estate strength is usually limited to residual formulation or method-of-use claims, which generally do not prevent generic penetration into the core market.

Where protection tends to concentrate post-expiry

• Specific release characteristics
• Manufacturing controls (less often a major market lever for a mature product)
• Specific dosing regimens (sometimes narrower than payers’ substitution rules)

Business consequence

Even if certain patents exist, market dynamics usually prioritize:

• payer substitutions
• pharmacy switch behavior
• net cost minimization

---

What patent litigation affects Namenda commercialization?

Short answer: Litigation risk for a mature, generic-dominated small molecule tends to be intermittent and episodic, usually tied to:

• specific patent listings covering certain strengths or formulations
• generic launch timing disputes
• settlement agreements that define “at-risk” launch windows

Why litigation matters financially now

For settled and expired products:

• litigation rarely changes long-term revenue structure
• it can, however, influence short windows of brand retention if settlements delayed a major generic entry wave

---

How does FDA approval status affect Namenda’s commercialization trajectory?

Short answer: Namenda is an established FDA-approved product; the major regulatory driver is not novelty but generic entry through ANDAs and labeling consistency (and, when applicable, any transitions between branded and generic or formulation versions).

Regulatory drivers that affect financials

• ANDA approvals expand supply.
• Labeling and bioequivalence acceptance drives substitution.
• Manufacturing site compliance can affect availability, influencing short-term fill rates.

---

What are generic entry risks for Namenda and what launch scenarios are most likely?

Short answer: The dominant “entry” risk is additional generic competition that further compresses price, not a binary risk of complete exclusion.

Likely launch scenarios

• Full generic launch across standard strengths, often with immediate substitution.
• Design-around for residual patents on specific formulations if any claims still apply.
• Authorized generics / branded generics that preserve channel access at lower net price, reducing the brand’s residual premium.

Financial outcomes tied to scenarios

• Most scenarios produce volume gains for generics and margin loss for the brand through net price compression.
• Any delayed launch reduces near-term erosion but does not typically reverse the long-run trend once ingredient protection is gone.

---

How does Namenda compare with leading Alzheimer’s therapies in market dynamics?

Short answer: Compared with newer Alzheimer’s agents (especially disease-modifying antibodies where market dynamics include coverage uncertainty and administration complexity), Namenda’s dynamic is stable and payer-driven, with less volatility and more direct cost-based competition.

Competitive positioning differences that affect demand

• Namenda competes against:
  • other symptomatic CNS agents and combination regimens
  • alternative Alzheimer’s symptom strategies
• New entrants change treatment narratives, but do not eliminate need for symptomatic memantine in moderate-to-severe disease pathways, supporting baseline demand.

---

What is the revenue trajectory pattern for Namenda at maturity?

Short answer: Mature CNS small molecules usually show:

• early brand growth followed by
• step-down in net price after generic entry and contract renegotiations
• a long tail of declining or flat-ish net sales dependent on adherence and formulary access

What to expect in a “brand-to-generic” trajectory

• Net sales are typically supported by:
  • persistence (patients remain on therapy)
  • switching inertia in specific prescriber networks
• Net price declines as:
  • payer switches to preferred generics
  • PBMs tighten substitution rules

Financial drivers beyond sales volume

• rebate intensity and contract structure
• channel mix (mail vs retail, specialty vs mainstream)
• state Medicaid and Medicare Part D plan design trends (formularies)

---

Key market and financial drivers checklist for Namenda

1. Generic penetration level by strength and dosage form
2. PBM formulary placement and step-edit restrictions
3. Net price trajectory from contract renegotiations and AWP-to-net spreads
4. Persistence/adherence in moderate-to-severe Alzheimer’s treated population
5. Combination therapy uptake (donepezil + memantine)
6. Supply continuity affecting fill rates and backorders
7. Residual patent/formulation islands only if they still block the most-used presentation

---

Key Takeaways

• Namenda’s market dynamics are dominated by payer-driven substitution and net price compression, not by active-ingredient exclusivity.
• The financial trajectory follows a mature CNS profile: stable chronic demand offset by ongoing brand margin erosion as generics expand and contracts tighten.
• Competitive pressure comes primarily from multi-source generic memantine, with any residual patent or formulation protections typically creating only incremental, short-duration protection rather than long-term market dominance.
• The core determinant of near-to-mid-term results is formulary and contracting strategy, not new regulatory milestones.

---

FAQs

1) Why does Namenda net price keep falling even when prescriptions remain stable?
Because PBM reimbursement structures and contract rebates typically anchor net cost to generic benchmarks after multi-source supply expands.

2) Does Namenda face biosimilar competition?
No. As a small molecule, it is not exposed to biosimilar market mechanics.

3) What most affects Namenda switching on pharmacy benefit formularies?
Preferred formulary status, copay differentials, step edits, and pharmacist substitution rules under plan design.

4) Can combination therapy with donepezil materially slow memantine generic erosion?
It can support persistence and reduce switching inertia, but it usually does not stop generic share gains once payers standardize on lowest-cost options.

5) What is the most common commercial “effect” of any remaining Orange Book patents on a mature drug like Namenda?
It typically affects when specific generic versions can launch, which can delay incremental volume shifts but rarely reverses long-term brand decline once broader entries are cleared.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Namenda (memantine). FDA.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
3. Centers for Medicare & Medicaid Services. (n.d.). Medicare Part D Drug Pricing and Formulary/Plan Information. CMS.

DrugChatter Q&A for NAMENDA

How much does namenda cost?
Does medicare cover namenda xr?
Namenda prescription assistance program?